AZD 1775

Drug Profile

AZD 1775

Alternative Names: AZD-1775; L001739996-008U; MK-1775 hemihydrate; MK1775

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer AstraZeneca; Cancer Research UK; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Washington
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Colorectal cancer; Glioblastoma; Haematological disorders; Head and neck cancer; Uterine cancer; Vulvovaginal cancer
  • Discontinued Cervical cancer

Most Recent Events

  • 21 Nov 2017 National Cancer Institute suspended phase I trial in Vulvovaginal and Uterine cancer in USA, before November 2017 (NCT03345784)
  • 14 Nov 2017 AstraZeneca plans a phase II study in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (NCT03330847)
  • 07 Nov 2017 AstraZeneca plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA in November 2017 (NCT03333824)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top